Sexually transmitted diseases and infections

Innovative Molecules raises €20 million Series A equity financing round

Retrieved on: 
Monday, June 7, 2021
Sexually transmitted diseases and infections, Medical specialties, Biology of bipolar disorder, Herpes simplex, Infectious diseases, Clinical medicine

Munich, Germany, June 7, 2021 - Innovative Molecules GmbH, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced the closing of its 20 million Series A equity financing round led by LSP (Life Sciences Partners).

Key Points: 
  • Munich, Germany, June 7, 2021 - Innovative Molecules GmbH, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced the closing of its 20 million Series A equity financing round led by LSP (Life Sciences Partners).
  • Joachim Rothe, Partner at LSP, complements: I am pleased with LSP leading the investment syndicate of Innovative Molecules.
  • Thomas Hoffmann, co-founder & financial advisor to Innovative Molecules, states: To have gained LSP as one of the leading European life sciences funds as the lead investor for this Series A financing round is truly a quality stamp for our project.
  • Innovative Molecules GmbH is a drug development company aiming for setting a new treatment standard for Herpes simplex induced diseases.

CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19

Retrieved on: 
Tuesday, June 1, 2021
Leronlimab, Retroviridae, Prevention of HIV/AIDS, HIV/AIDS, Drugs, Sexually transmitted diseases and infections, Medical specialties, Management of HIV/AIDS, HIV, Triple-negative breast cancer, CCR5 receptor antagonist

Philippine Airlines (PAL) has stepped up to help with one of the main challenges, the long delivery time from the USA to the Philippines.

Key Points: 
  • Philippine Airlines (PAL) has stepped up to help with one of the main challenges, the long delivery time from the USA to the Philippines.
  • Filipinos can get more information on how to access leronlimab in the Philippines by contacting CytoDyns local distribution partner Chiral Pharma Corporation.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • Leronlimab does not work on other strains of HIV (for example X4), however R5 is the most dominant strain of HIV.

Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

Retrieved on: 
Tuesday, June 1, 2021
Infectious causes of cancer, Chlamydiae, Sexually transmitted diseases and infections, Medical specialties, Pathogenic bacteria, Bacteria, Clinical medicine, Mycoplasma, Lactic acid/citric acid/potassium bitartrate, Sexually transmitted infection, Bitartrate, Chlamydia

Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).

Key Points: 
  • Evofem Biosciences, Inc., (NASDAQ:EVFM) is developing and commercializing innovativeproducts to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).
  • The Company launched its first FDA-approved commercial product, Phexxi (lactic acid, citric acid and potassium bitartrate), inthe United StatesinSeptember 2020.
  • The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD .'
  • Phexxiis a registered trademark of Evofem Biosciences, Inc.

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Retrieved on: 
Thursday, May 27, 2021
Clinical medicine, Medicine, Medical specialties, Sexually transmitted diseases and infections, Virotherapy, Cancer immunotherapy, Immunotherapy, Oncolytic virus, Herpes simplex virus, Virus, Herpes simplex

Oncorus novel Synthetic vRNA approach holds the potential for IV-administration and avoids the challenge of neutralizing antibodies seen in previous approaches with IV-administered OVs.

Key Points: 
  • Oncorus novel Synthetic vRNA approach holds the potential for IV-administration and avoids the challenge of neutralizing antibodies seen in previous approaches with IV-administered OVs.
  • Simultaneously, the therapeutic benefit of viral immunotherapy has been limited to intratumoral (iTu) administration, restricting broader applications of this modality.
  • Christophe Quva, Ph.D., Oncorus Chief Scientific Officer, said, We are proud of our teams work to advance both our oncolytic Herpes Simplex Virus and Synthetic Viral RNA Immunotherapy Platforms.
  • At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients.

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

Retrieved on: 
Thursday, May 27, 2021
Cancer, Clinical medicine, Medicine, Infectious causes of cancer, Papillomavirus, Otorhinolaryngology, Health effects of tobacco, Sexually transmitted diseases and infections, Human papillomavirus infection, Head and neck cancer, Immunotherapy, Head and Neck Cancer Alliance

FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.

Key Points: 
  • FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.
  • Because head and neck cancer is often diagnosed at later stages, treatment is often more difficult and more invasive.
  • There are exciting things happening in clinical research for head and neck cancer therapies, said Amanda Hollinger, Executive Director of HNCA.
  • In 2018, head and neck cancer surpassed cervical cancer as the most common HPV-attributed cancer in the United States.

New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021

Retrieved on: 
Monday, May 17, 2021
Infectious causes of cancer, Chlamydiae, Sexually transmitted diseases and infections, Medical specialties, Gonorrhea, Pathogenic bacteria, Chlamydia, Clinical medicine, Infectious diseases

All participants indicated that this information was important to know for women considering a microbicidal vaginal gel like EVO100.\nAbstracts have been published in the May 2021 issue of Value in Health1, the international journal of ISPOR.

Key Points: 
  • All participants indicated that this information was important to know for women considering a microbicidal vaginal gel like EVO100.\nAbstracts have been published in the May 2021 issue of Value in Health1, the international journal of ISPOR.
  • The poster is available to registered Virtual ISPOR 2021 attendees at https://virtualispor2021.secure-platform.com/a/organizations/main/home and will be available following the conference at https://www.evofem.com/posters-and-publications/ .\nEnrollment is underway in EVOGUARD, the pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women.
  • All 90 planned study centers have been identified and more than 80 sites have been activated.
  • The Company expects to complete enrollment by year-end 2021 and to report top-line data in mid-2022.

Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women

Retrieved on: 
Wednesday, May 12, 2021
Infectious causes of cancer, Sexually transmitted diseases and infections, Chlamydiae, Gonorrhea, Chlamydia, Food and Drug Administration, Medical specialties, Health, Clinical medicine

b'SAN DIEGO, May 12, 2021 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women.

Key Points: 
  • b'SAN DIEGO, May 12, 2021 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women.
  • "\nEVO100 previously received Fast Track designation from the FDA for the prevention of chlamydia in women and was also designated as a Qualified Infectious Disease Product (QIDP) by the FDA for the prevention of gonorrhea in women.
  • A drug that receives QIDP designationmay qualify for an additional five years of marketing exclusivity.\nEvofem\'s pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women, EVOGUARD , is currently enrolling 1,730 women in U.S. study sites.
  • This double-blinded, placebo-controlled study of EVO100 met its primary and secondary efficacy endpoints, with statistically significant reductions in the risk of chlamydia and gonorrhea infections.

SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Infectious diseases, Health, Science, Research, Infectious causes of cancer, Medical specialties, Gonorrhea, Clinical medicine, Medicine, Sexually transmitted diseases and infections, Chlamydiae, Pathogenic bacteria, Neisseria gonorrhoeae, Antimicrobial resistance, Neisseria, Chlamydia

SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones.

Key Points: 
  • SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones.
  • Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae, while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments.
  • SpeeDx will utilize their newly patented InSignia\xe2\x84\xa2 technology to both assess the presence of active bacterial infection and AMR status.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.

Global Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) Market Report 2020: Market Revenue by Segment and Market Outlooks 2015-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021
Infectious diseases, General Health, Health, Chlamydiae, Infectious causes of cancer, Sexually transmitted diseases and infections, Medical specialties, Pathogenic bacteria, Chlamydia, Market analysis, Infectious diseases, In vitro, Clinical medicine

b'The "Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nMultiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Multiparameter CT/NG NAAT Tests market for the year 2020 and beyond.

Key Points: 
  • b'The "Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com\'s offering.\nMultiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.\nThe model discusses in detail the impact of COVID-19 on Multiparameter CT/NG NAAT Tests market for the year 2020 and beyond.
  • Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis.
  • Model covers Dual CT/NG Multiparameter NAAT testing.\nEach of the covered 39 country\'s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes.
  • In addition, analysts provide unique country specific insights on the market.\nSWOT analysis for Multiparameter CT/NG NAAT Tests market.\nCompetitive dynamics insights and trends provided for Multiparameter CT/NG NAAT Tests market.\nDrive the understanding of the market by getting the veritable big picture including an overview of the healthcare system.

2021 Epidemiology Forecast for the Global Herpes Market to 2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Health, General Health, Medical specialties, Sexually transmitted diseases and infections, Medicine, Virology, Viral diseases, Biology of bipolar disorder, Herpes simplex, Herpes, Disease

b'The "Global Herpes Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Herpes epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Herpes Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Herpes epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Herpes patients, history of the disease at the population level (Herpes prevalence, Herpes incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Herpes patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Herpes market sizing, assessing market potential, and developing drug forecast models\nIdentify Herpes patients segments through age groups, gender, and disease sub-types\n'